Clinical trials: Papilloma Virus, Human
Human Papillomavirus-Related Cervical Carcinoma
Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort
Human papillomaviruses (HPVs) are the most common of sexually transmitted viral agents and they are associated with genital and oral diseases.
- Trial name
- PAPILLOR (NCT02774538)
- Testing
- Agreement between oral and cervical HPV infection
- Where
- 4 sites in France
- Volunteers
- 165 people
- Sponsor
- Institut de Cancérologie de Lorraine
Human Papillomavirus
Human Papillomavirus (HPV) Vaccination Among Survivors of Childhood Cancer
This study will focus on the primary objectives: To estimate the prevalence of HPV vaccination among a large cohort of childhood cancer survivors and an acquaintance control group.
- Trial name
- NCT01117389
- Where
- United States
- Volunteers
- 587 people
- Sponsor
- St. Jude Children's Research Hospital
Oropharyngeal Neoplasms
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer
This clinical trial studies the intensity of adjuvant ("helper") therapy required in p16 positive oropharynx cancer patients, who have had all known disease removed surgically by a minimally invasive approach, and who have…
- Trial name
- ADEPT (NCT01687413)
- Testing
- Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Human Papillomavirus Infection, HPV
Human Papillomavirus in Young People Epidemiological Research 3
Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV.
- Conditions
- Human Papillomavirus Infection, HPV, HPV Infection, Anal Cancer
- Trial name
- HYPER3 (NCT05587725)
- Where
- Australia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Monash University
Condylomata Acuminata
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
The purpose of this study is to investigate the clinical efficacy, safety and tolerability of a Polyphenon E Ointment 10% and a Polyphenon E Ointment 15% in the treatment of external genitial warts in male and female patients.
- Trial name
- NCT00449982
- Testing
- Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
- Where
- 12 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- MediGene
Common Warts, Common Warts (Verruca Vulgaris)
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 [Cantharidin and Occlusion in Verruca Epithelium 5]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal…
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Trial name
- COVE-5 (NCT07881952)
- Testing
- VP-102
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Verrica Pharmaceuticals Inc.
AIN, HIV
HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)
This study evaluates vaccination with the quadrivalent HPV vaccine (Gardasil) versus placebo vaccination on prevention of high grade AIN recurrence in HIV-positive MSM (men who have sex with men) who were successfully treated for…
- Trial name
- VACCAIN-P (NCT02087384)
- Testing
- Gardasil
- Where
- 3 sites in Netherlands
- Volunteers
- 126 people
- Sponsor
- Prof. Jan Prins
Neoplasms, Glandular and Epithelial, Diphtheria
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)
Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and…
- Conditions
- Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus, Whooping Cough
- Trial name
- NCT00337428
- Testing
- Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF), Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF), Comparator: REPEVAX™ (Concomitant)
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Cervical Cancer
Promise Women Project
The goal of this study is to develop and test an intervention program to improve cervical cancer prevention among Muslim American women.
- Trial name
- NCT05862844
- Testing
- Promise women project (Promote Cervical Cancer Prevention Methods Among Muslim Women in Virginia )
- Where
- 4 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mark Dignan, PhD
Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols.
- Trial name
- PATHOS (NCT02215265)
- Testing
- Cisplatin, Postoperative radiotherapy
- Where
- 57 sites in United States, Australia and 3 more
- Volunteers
- 1,269 people
- Sponsor
- Lisette Nixon
Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis
M7824 in People With Recurrent Respiratory Papillomatosis
Background: Programmed cell death protein 1 (PD-L1) is a protein on the surface of cells. It regulates if a cell can be killed by immune system cells.
- Conditions
- Recurrent Respiratory Papillomatosis, Respiratory Papillomatosis, Laryngeal Papilloma, Recurrent, Human Papilloma Virus
- Trial name
- NCT03707587
- Testing
- M7824
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Acceptability and Feasibility of Human Papilloma Virus Vaccine
The overall program goal is to determine the Acceptability and Feasibility of introducing a population based Human Papilloma Virus (HPV) Vaccination programme and understanding the key individual and community factors that would…
- Trial name
- NCT01209338
- Testing
- Health education
- Where
- India
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tata Memorial Hospital
HPV-Related Carcinoma, HPV Infection
Determining the Frequency of Occurrence and Defining the Most Appropriate Screening Test for Anal Intraepithelial Neoplasia (AIN) in Patients With Human Papillomavirus (HPV) Related Gynecological Diseases.
The primary aim of the study is to determine the total risk of AIN in group of HPV-RGD survivors and additionally to establish an exact risk for each of HPV-related gynecological precancers/cancers.
- Trial name
- NCT06574087
- Testing
- hrHPV test and cytology
- Where
- Poland
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- PCK Marine Hospital in Gdynia
Papillomavirus Infections, Coronavirus Disease (COVID-19)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
The purpose of this study to evaluate the safety and immunogenicity of a 2-dose regimen of 9vHPV vaccine, where the first dose is administered concomitantly with a first dose of a 2-dose regimen of mRNA-1273 vaccine versus…
- Trial name
- NCT05119855
- Testing
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Where
- 38 sites in United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus, Papillomavirus Vaccines
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control.
- Trial name
- NCT00294047
- Testing
- Cervarix
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 5,752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus (HPV) Infection, Cervical Cancer
Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix.
The purpose of this study is to evaluate the clinical efficacy and safety of Cnidium Monnieri Detoxification Formula in clearing HPV infection, improving clinical symptoms and quality of life in female patients with persistent…
- Trial name
- NCT06705322
- Testing
- Cnidium Monnieri Detoxification Formula
- Volunteers
- 79 people
- Sponsor
- Fudan University
Human Papillomavirus-Related Malignant Neoplasm
Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions
This is an single arm clinical study of the safety and efficacy of T512 to possibly treat cervical intraepithelial neoplasia(CIN).
- Trial name
- NCT03226470
- Testing
- T512
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
STI
Population Burden of STI and Implication for Intervention in Hong Kong
This is a 5-year cross-disciplinary sexually transmitted infection (STI) project involving a) territory-wide and community-based studies (survey and specimen collection); b) simulation of STI transmission dynamics and comparison…
- Trial name
- NCT04793841
- Testing
- self-sampling kits for STI testing in laboratory
- Where
- Hong Kong
- Volunteers
- 1,977 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Papillomavirus Infections
Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
This is a 96-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age.
- Trial name
- NCT04708041
- Testing
- 9vHPV vaccine
- Where
- 30 sites in United States, Colombia and 4 more
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus
Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology
The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood.
- Trial name
- DEP-HPV (NCT04901351)
- Testing
- Smear
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Toulouse
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.